162 related articles for article (PubMed ID: 20806971)
1. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology.
Chen YT; Chen CL; Chen HW; Chung T; Wu CC; Chen CD; Hsu CW; Chen MC; Tsui KH; Chang PL; Chang YS; Yu JS
J Proteome Res; 2010 Nov; 9(11):5803-15. PubMed ID: 20806971
[TBL] [Abstract][Full Text] [Related]
2. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients.
Chen CL; Lai YF; Tang P; Chien KY; Yu JS; Tsai CH; Chen HW; Wu CC; Chung T; Hsu CW; Chen CD; Chang YS; Chang PL; Chen YT
J Proteome Res; 2012 Dec; 11(12):5611-29. PubMed ID: 23082778
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis.
Li C; Li H; Zhang T; Li J; Liu L; Chang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1047-52. PubMed ID: 24661883
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis.
Lei T; Zhao X; Jin S; Meng Q; Zhou H; Zhang M
Clin Genitourin Cancer; 2013 Mar; 11(1):56-62. PubMed ID: 22982111
[TBL] [Abstract][Full Text] [Related]
7. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients.
Mueller J; von Eggeling F; Driesch D; Schubert J; Melle C; Junker K
Eur Urol; 2005 Jun; 47(6):885-93; discussion 893-4. PubMed ID: 15925088
[TBL] [Abstract][Full Text] [Related]
8. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of bladder cancer by analysis of urinary fibronectin.
Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
[TBL] [Abstract][Full Text] [Related]
10. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
11. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
13. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
14. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
15. Systematic quantification of peptides/proteins in urine using selected reaction monitoring.
Selevsek N; Matondo M; Sanchez Carbayo M; Aebersold R; Domon B
Proteomics; 2011 Mar; 11(6):1135-47. PubMed ID: 21360671
[TBL] [Abstract][Full Text] [Related]
16. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
17. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
18. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
19. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
20. Comparison of seven screening methods in the diagnosis of bladder cancer.
Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
